Zymeworks Inc. (ZYME) Income Statement
ZYME 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsZYME revenue and net income
Where ZYME's revenue goes
2025Each bar shows an amount and its share of revenue. ZYME kept −76.6% of revenue as net income.
ZYME profit margins
ZYME growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +38.9% | −36.4% | +22.2% | +27.1% |
| Gross profit | +38.9% | −36.4% | +22.2% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZYME quarterly EPS vs estimates
Zymeworks beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 5, 2026 (estimate $2.50).
ZYME income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M | $26.7M | $39.0M | $29.5M | $53.0M | $51.8M | $11.0M |
| Cost of revenue | $10.8M | $11.2M | $143.0M | $208.7M | $199.5M | $170.9M | $117.1M | $56.9M | $41.1M | $35.6M |
| Gross profit | $106.0M | $76.3M | −$67.0M | $412.5M | $26.7M | $39.0M | −$87.6M | $53.0M | $10.6M | −$24.5M |
| Research & development | $137.0M | $134.6M | $143.6M | $208.6M | $199.8M | $168.5M | $118.2M | $56.7M | $41.7M | $36.8M |
| Sales, general & admin | $61.5M | $61.5M | $70.4M | $73.4M | $42.6M | $57.9M | $62.7M | $29.5M | $18.6M | $12.6M |
| Total operating expenses | $198.5M | $213.4M | $71.1M | $282.0M | $242.3M | $226.4M | $63.7M | $86.1M | $59.2M | $48.1M |
| Operating income | −$92.5M | −$137.1M | −$138.1M | $130.5M | −$215.6M | −$187.5M | −$151.3M | −$33.1M | −$9.0M | −$37.9M |
| Interest income | $13.4M | $19.9M | $19.7M | $3.6M | $2.5M | $5.7M | $6.0M | $2.6M | $743,000 | $308,000 |
| Interest expense | — | — | — | $3.6M | $12.9M | $17.6M | $11.1M | $166,000 | $1.1M | $950,000 |
| Income before taxes | −$79.8M | −$116.6M | −$119.2M | $135.2M | −$212.4M | −$180.1M | −$144.9M | −$34.4M | −$10.0M | −$38.9M |
| Income taxes | $1.4M | $6.1M | −$568,000 | $10.9M | −$516,000 | $429,000 | $582,000 | $2.2M | $444,000 | −$5.1M |
| Net income | −$81.1M | −$122.7M | −$118.7M | $124.3M | −$211.8M | −$180.6M | −$145.4M | −$36.6M | −$10.4M | −$33.8M |
| EBITDA | −$68.6M | −$108.6M | −$120.7M | $142.5M | −$206.1M | −$177.2M | −$143.1M | −$29.5M | −$6.1M | −$36.3M |
| EPS (diluted) | −$1.08 | −$1.61 | −$1.73 | $1.77 | −$4.11 | −$3.58 | −$3.65 | −$1.35 | −$2.34 | −$0.36 |
| Gross margin | 100.0% | 100.0% | −88.1% | 100.0% | 100.0% | 100.0% | −296.3% | 100.0% | 20.5% | −222.9% |
| Operating margin | −87.3% | −179.7% | −181.6% | 31.6% | −808.2% | −481.3% | −512.1% | −62.5% | −17.4% | −343.9% |
| Net margin | −76.6% | −160.8% | −156.1% | 30.1% | −794.0% | −463.5% | −492.3% | −68.9% | −20.1% | −307.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $2.4M | $2.5M | $27.6M | $48.7M | $27.1M | $31.0M | $16.0M | $19.2M | $10.0M | $16.9M | $16.5M |
| Cost of revenue | $0 | $2.8M | $1.7M | $0 | $3.2M | $3.3M | −$26.7M | $2.7M | $2.5M | $32.7M | $25.2M | $32.9M |
| Gross profit | $4.6M | −$439,000 | $824,000 | $27.6M | $48.7M | $27.1M | $31.0M | $16.0M | $19.2M | $10.0M | $16.9M | $16.5M |
| Research & development | $32.0M | $2.41B | $31.2M | $35.6M | $34.4M | $35.7M | $37.1M | $36.4M | $29.2M | $32.0M | $25.5M | $32.8M |
| Sales, general & admin | $19.3M | $15.07B | $13.7M | $14.1M | $14.9M | $17.0M | $16.2M | $13.9M | $15.7M | $1.2M | $14.8M | $17.0M |
| Total operating expenses | $46.8M | $46.7M | $45.0M | $49.7M | $49.4M | $52.7M | $53.2M | $50.2M | $62.1M | $47.8M | $40.3M | $49.7M |
| Operating income | −$42.2M | −$47.1M | −$44.2M | −$22.1M | −$674,000 | −$25.6M | −$22.2M | −$34.2M | −$42.9M | −$37.8M | −$23.4M | −$33.2M |
| Interest income | $3.3M | $2.7M | $3.0M | $3.5M | $3.4M | $3.4M | $4.1M | $4.8M | $5.2M | $5.9M | $5.0M | $5.0M |
| Interest expense | $6.59B | $2.1M | — | — | $0 | $0 | — | — | — | — | $7.2M | — |
| Income before taxes | −$45.3M | −$46.4M | −$41.5M | −$18.3M | $2.1M | −$22.1M | −$17.8M | −$29.6M | −$37.6M | −$31.6M | −$19.2M | −$27.6M |
| Income taxes | −$273,000 | −$2.2M | −$270,000 | $1.3M | −$186,000 | $496,000 | $5.7M | $226,000 | $68,000 | $75,000 | −$4.7M | $1.1M |
| Net income | −$45.0M | −$44.2M | −$41.2M | −$19.6M | $2.3M | −$22.6M | −$23.5M | −$29.9M | −$37.7M | −$31.7M | −$14.5M | −$28.7M |
| EBITDA | −$43.3M | −$41.4M | −$39.8M | −$15.7M | $2.6M | −$22.3M | −$18.5M | −$31.6M | −$23.1M | −$20.9M | −$20.0M | −$26.7M |
| EPS (diluted) | −$0.62 | −$0.59 | −$0.55 | −$0.26 | $0.03 | −$0.30 | −$0.31 | −$0.39 | −$0.49 | −$0.42 | −$0.20 | −$0.41 |
| Gross margin | 100.0% | −18.2% | 32.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −919.0% | −1,956.7% | −1,755.5% | −80.1% | −1.4% | −94.5% | −71.6% | −213.8% | −222.9% | −376.9% | −138.4% | −201.4% |
| Net margin | −980.8% | −1,834.0% | −1,638.5% | −71.0% | 4.8% | −83.5% | −75.8% | −186.6% | −195.8% | −315.6% | −85.6% | −173.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZYME's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZYME financial results
In fiscal year 2025 (ended December 31, 2025), Zymeworks reported revenue of $106.0 million, up 38.9% from the year before. It had a net loss of $81.1 million, a net profit margin of −76.6%. Diluted earnings per share came to −$1.08. Over five years revenue grew at an average rate of 22.2% a year.
See the ZYME stock overview for the latest quote and news, or the ZYME chart for price history and technical indicators.
ZYME income statement FAQ
What is Zymeworks's annual revenue?
Zymeworks reported total revenue of $106.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 38.9% from $76.3 million the previous year.
Is Zymeworks profitable?
No. Zymeworks reported a net loss of $81.1 million in fiscal 2025, a net profit margin of −76.6%; its operating margin was −87.3%.
What is Zymeworks's gross margin?
Zymeworks's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Zymeworks kept $100 after the direct cost of its products and services.
How much does Zymeworks spend on research and development?
Zymeworks spent $137.0 million on research and development in fiscal 2025, 129.3% of revenue.
How fast is Zymeworks growing?
Revenue grew 22.2% a year on average over the last five fiscal years, from $39.0 million to $106.0 million.
What are Zymeworks's earnings per share?
Zymeworks earned $-1.08 per diluted share in fiscal 2025, compared with $-1.61 a year earlier.
When will Zymeworks report its next earnings?
Zymeworks is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Zymeworks's fiscal year end?
Zymeworks's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.